UY35997A - Derivados de isoquinoleína, su procedimiento de preparación y las composiciones farmacéuticas que los contienen - Google Patents

Derivados de isoquinoleína, su procedimiento de preparación y las composiciones farmacéuticas que los contienen

Info

Publication number
UY35997A
UY35997A UY0001035997A UY35997A UY35997A UY 35997 A UY35997 A UY 35997A UY 0001035997 A UY0001035997 A UY 0001035997A UY 35997 A UY35997 A UY 35997A UY 35997 A UY35997 A UY 35997A
Authority
UY
Uruguay
Prior art keywords
isoquinoleine
derivatives
pharmaceutical compositions
compositions containing
preparation procedure
Prior art date
Application number
UY0001035997A
Other languages
English (en)
Inventor
Poitevin Christophe
Françoise Gellibert
Konnert Marc
Jean-Louis Peglion
Goument Bertrand
AIMéE DESSINGES
Jean-Paul Vilaine
Villeneuve Nicole
Chimenti Stefano
Courchay Christine
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of UY35997A publication Critical patent/UY35997A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings

Abstract

Compuesto de fórmula (I):en la que los sustituyentes son tales como se definen en la reivindicación 1. Medicamentos.
UY0001035997A 2014-02-21 2015-02-12 Derivados de isoquinoleína, su procedimiento de preparación y las composiciones farmacéuticas que los contienen UY35997A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1451389A FR3017868A1 (fr) 2014-02-21 2014-02-21 Derives d'isoquinoleine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (1)

Publication Number Publication Date
UY35997A true UY35997A (es) 2015-08-31

Family

ID=50424640

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035997A UY35997A (es) 2014-02-21 2015-02-12 Derivados de isoquinoleína, su procedimiento de preparación y las composiciones farmacéuticas que los contienen

Country Status (38)

Country Link
US (1) US9809553B2 (es)
EP (1) EP3107900B1 (es)
JP (1) JP6491226B2 (es)
KR (1) KR102251198B1 (es)
CN (1) CN105980361B (es)
AR (1) AR099493A1 (es)
AU (1) AU2015220659B2 (es)
BR (1) BR112016017679B1 (es)
CA (1) CA2938344C (es)
CL (1) CL2016002089A1 (es)
CY (1) CY1120034T1 (es)
DK (1) DK3107900T3 (es)
EA (1) EA030617B1 (es)
ES (1) ES2659885T3 (es)
FR (1) FR3017868A1 (es)
HK (1) HK1232220A1 (es)
HR (1) HRP20180141T1 (es)
HU (1) HUE038337T2 (es)
IL (1) IL246721B (es)
JO (1) JO3372B1 (es)
LT (1) LT3107900T (es)
MA (1) MA39207A1 (es)
ME (1) ME02863B (es)
MX (1) MX363301B (es)
MY (1) MY178745A (es)
NO (1) NO3107900T3 (es)
NZ (1) NZ722513A (es)
PL (1) PL3107900T3 (es)
PT (1) PT3107900T (es)
RS (1) RS56766B1 (es)
RU (1) RU2679621C2 (es)
SG (1) SG11201605662TA (es)
SI (1) SI3107900T1 (es)
TW (1) TWI547484B (es)
UA (1) UA117953C2 (es)
UY (1) UY35997A (es)
WO (1) WO2015124877A1 (es)
ZA (1) ZA201604976B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2898336T3 (es) * 2016-06-17 2022-03-07 Dae Woong Pharma Derivado de difenilmetano en forma cristalina
CN112839647A (zh) * 2018-06-07 2021-05-25 达萨玛治疗公司 Sarm1抑制剂
EP3818046B1 (en) * 2018-07-02 2023-05-10 Ecole Polytechnique Federale De Lausanne (Epfl) Lactate enhancing compounds and uses thereof
US11248004B2 (en) 2018-11-06 2022-02-15 Cervello Therapeutics, Llc. Substituted isoquinolines as rock kinase inhibitors
KR20210093269A (ko) 2018-11-06 2021-07-27 써벨로 테라퓨틱스, 엘엘씨 Rock 키나아제 저해제
WO2021087112A1 (en) 2019-10-30 2021-05-06 Biogen Ma Inc. Condensed bi-heterocycles as inhibiting agents for bruton's tyrosine kinase
CN115974647A (zh) * 2022-12-05 2023-04-18 江苏宏邦化工科技有限公司 以四氢-4-甲基-2-苯基-2h-吡喃-4-醇为原料制备苯乐戊醇的方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0187371B1 (en) 1984-12-27 1991-06-19 Asahi Kasei Kogyo Kabushiki Kaisha Substituted isoquinolinesulfonyl compounds
JPH07277979A (ja) * 1994-04-12 1995-10-24 Asahi Chem Ind Co Ltd 過粘性症候群治療または予防剤
US6794398B1 (en) 1999-04-27 2004-09-21 Mitsubishi Pharma Corporation Preventive/remedies for liver diseases
EP1320367A4 (en) * 2000-08-11 2007-01-17 Purdue Research Foundation PROCESS FOR THE PRODUCTION OF DINAPSOLIN
PL369108A1 (en) * 2001-09-06 2005-04-18 Schering Corporation 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
MXPA04007191A (es) * 2002-01-23 2005-03-31 Bayer Pharmaceuticals Corp Derivados de pirimidina como inhibidores de rho-quinasa.
JP2007008816A (ja) 2003-10-15 2007-01-18 Ube Ind Ltd 新規イソキノリン誘導体
CN101213187B (zh) * 2005-06-28 2012-06-06 塞诺菲-安万特股份有限公司 作为rho-激酶抑制剂的异喹啉衍生物
CA2615663C (en) 2005-07-26 2013-10-15 Sanofi-Aventis Cyclohexylamin isoquinolone derivatives as rho-kinase inhibitors
ES2423006T3 (es) 2005-07-26 2013-09-17 Sanofi Derivados de isoquinolona sustituidos con piperidinilo como inhibidores de la cinasa Rho
US7867999B1 (en) * 2005-12-22 2011-01-11 Alcon Research, Ltd. Hydroxyamino- and amino-substituted pyridine analogs for treating rho kinase-mediated diseases and conditions
US7893088B2 (en) * 2006-08-18 2011-02-22 N.V. Organon 6-substituted isoquinoline derivatives
CN101616909B (zh) 2006-12-27 2013-09-11 塞诺菲-安万特股份有限公司 作为Rho-激酶抑制剂的被取代的异喹啉和异喹啉酮衍生物
EP2114920A1 (en) 2006-12-27 2009-11-11 Sanofi-Aventis Substituted isoquinoline and isoquinolinone derivatives
DE602007013295D1 (de) * 2006-12-27 2011-04-28 Sanofi Aventis Substituierte isochinoline und ihre verwendung als rho-kinase-inhibitoren
MY151953A (en) 2006-12-27 2014-07-31 Sanofi Aventis Cycloalkylamine substituted isoquinoline derivatives
CN101573338B (zh) 2006-12-27 2013-03-20 塞诺菲-安万特股份有限公司 环烷基胺取代的异喹诺酮和异喹啉酮衍生物
DE602007010981D1 (de) 2006-12-27 2011-01-13 Sanofi Aventis Cycloalkylaminsubstituierte isochinolin- und isochinolinonderivate
TW200845988A (en) * 2007-04-05 2008-12-01 Astrazeneca Ab New compounds and their uses 707
BRPI0914330A2 (pt) 2008-06-24 2019-09-24 Sanofi Aventis derivados de isoquinolina e isoquinolinona substituídos bl-e policíclicos
US8541449B2 (en) 2008-06-24 2013-09-24 Sanofi Substituted isoquinolines and isoquinolinones as Rho kinase inhibitors
CN102131785B (zh) 2008-06-24 2014-10-29 赛诺菲-安万特 6-取代的异喹啉和异喹啉酮

Also Published As

Publication number Publication date
SG11201605662TA (en) 2016-08-30
MX363301B (es) 2019-03-20
HRP20180141T1 (hr) 2018-03-09
AU2015220659A1 (en) 2016-08-04
MY178745A (en) 2020-10-20
JO3372B1 (ar) 2019-03-13
PT3107900T (pt) 2018-01-08
BR112016017679B1 (pt) 2022-07-26
MX2016010779A (es) 2016-10-26
EA030617B1 (ru) 2018-08-31
RU2016137502A3 (es) 2018-09-24
RU2679621C2 (ru) 2019-02-12
CY1120034T1 (el) 2018-12-12
JP6491226B2 (ja) 2019-03-27
HUE038337T2 (hu) 2018-10-29
CL2016002089A1 (es) 2017-01-27
AR099493A1 (es) 2016-07-27
JP2017506251A (ja) 2017-03-02
WO2015124877A1 (fr) 2015-08-27
RU2016137502A (ru) 2018-03-27
CA2938344C (fr) 2018-07-03
ME02863B (me) 2018-04-20
KR20160116003A (ko) 2016-10-06
CN105980361B (zh) 2019-05-21
US20170137385A1 (en) 2017-05-18
CN105980361A (zh) 2016-09-28
CA2938344A1 (fr) 2015-08-27
AU2015220659B2 (en) 2018-09-13
ES2659885T3 (es) 2018-03-19
RS56766B1 (sr) 2018-04-30
SI3107900T1 (en) 2018-02-28
EP3107900A1 (fr) 2016-12-28
LT3107900T (lt) 2017-12-27
BR112016017679A2 (es) 2017-08-08
TWI547484B (zh) 2016-09-01
ZA201604976B (en) 2022-05-25
US9809553B2 (en) 2017-11-07
EA201691675A1 (ru) 2017-02-28
TW201534587A (zh) 2015-09-16
NO3107900T3 (es) 2018-04-14
KR102251198B1 (ko) 2021-05-11
NZ722513A (en) 2019-08-30
IL246721B (en) 2018-12-31
EP3107900B1 (fr) 2017-11-15
UA117953C2 (uk) 2018-10-25
PL3107900T3 (pl) 2018-04-30
DK3107900T3 (en) 2018-02-19
MA39207A1 (fr) 2017-04-28
FR3017868A1 (fr) 2015-08-28
HK1232220A1 (zh) 2018-01-05

Similar Documents

Publication Publication Date Title
NI201800133A (es) Nuevos derivados piperidinilo sustituidos con (hetero) arilo, un proceso para su preparación y composiciones farmacéuticas que los contienen
ECSP17081744A (es) Nuevos derivados hidroxiéster,un proceso para su preparación y composiciones farmacéuticas que los contienen
NI201800132A (es) Nuevos derivados piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen
NI201400079A (es) Nuevos derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
EA201890126A1 (ru) Новые бициклические производные, способ их получения и фармацевтические композиции, содержащие их
CO7210068A1 (es) Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen
NI201400080A (es) Nuevos derivados fosfatos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
UY35997A (es) Derivados de isoquinoleína, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
DOP2016000014A (es) Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CR20170008A (es) Compuestos de [1,2,4] triazol e imidazol sustituidos
UY35653A (es) Nuevos derivados de indol y de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
DOP2018000083A (es) NUEVOS DERIVADOS DE IMIDAZO[4,5-b]PIRIDINA, UN PROCESO PARA SU PREPARACIÓN Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN
CL2018001493A1 (es) Nuevos derivados de fenilo
CR20160448A (es) Nuevos derivados de piridina
ECSP16096831A (es) Derivados de naftiridinadiona
NI202000028A (es) Nuevos derivados macrocíclicos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
UY34761A (es) Composiciones parasiticidas que comprenden derivados de benzimidazol, métodos y usos de los mismos.
CO2017007074A2 (es) Sintesis total de trioxacarcina dc-45-a2 y preparación de analogos de trioxacarcina